Literature DB >> 17924445

The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection.

J Judy Chang1, Alexander J V Thompson, Kumar Visvanathan, Stephen J Kent, Paul U Cameron, Fiona Wightman, Paul Desmond, Stephen A Locarnini, Sharon R Lewin.   

Abstract

UNLABELLED: Hepatitis B virus (HBV)-specific T cells play a key role in clearance of the virus and in the pathogenesis of liver disease. Peripheral blood (n = 25) and liver biopsies (n = 19) were collected from individuals with chronic untreated HBV infection. Whole blood, cultured peripheral blood mononuclear cells (PBMCs), and cultured liver-infiltrating lymphocytes (LILs) were each stimulated with an overlapping peptide library to the whole HBV genome. The expression of T helper 1 (Th1) cytokines [interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), and interleukin 2 (IL-2)] and interleukin 10 (IL-10) was analyzed by intracellular cytokine staining and flow cytometry. In ex vivo whole blood, more lymphocytes produced Th1 cytokines than IL-10. When comparing cultured LILs with cultured PBMCs, we found a significantly higher magnitude of CD8(+) T cells from the liver producing IL-10 (P = 0.044), primarily in hepatitis B e antigen positive (HBeAg(+)) individuals. A positive correlation resulted between the magnitude of HBV-specific TNF-alpha(+) CD4(+) T cells in the liver and the degree of liver inflammation and fibrosis (P = 0.002 and P = 0.006, respectively).
CONCLUSION: The differences in cytokine production from HBV-specific T cells in blood and liver may explain the capacity for HBV to persist in the absence of significant hepatic destruction and highlights the balance between cytokine-mediated viral control and liver damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17924445     DOI: 10.1002/hep.21844

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

Review 1.  Living in the liver: hepatic infections.

Authors:  Ulrike Protzer; Mala K Maini; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2012-02-24       Impact factor: 53.106

2.  No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.

Authors:  Megan Crane; Sunee Sirivichayakul; J Judy Chang; Anchalee Avihingsanon; Sasiwimol Ubolyam; Supranee Buranapraditkun; Pattarawat Thantiworasit; Fiona Wightman; Stephen Locarnini; Gail Matthews; Gregory J Dore; Kiat Ruxrungtham; Sharon R Lewin
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

3.  Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis.

Authors:  David E Kaplan; Fusao Ikeda; Yun Li; Nobuhiro Nakamoto; Sutharsan Ganesan; Mary E Valiga; Frederick A Nunes; K Rajender Reddy; Kyong-Mi Chang
Journal:  J Hepatol       Date:  2008-03-07       Impact factor: 25.083

Review 4.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

5.  Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.

Authors:  J Judy Chang; Sunee Sirivichayakul; Anchalee Avihingsanon; Alex J V Thompson; Peter Revill; David Iser; John Slavin; Supranee Buranapraditkun; Pip Marks; Gail Matthews; David A Cooper; Stephen J Kent; Paul U Cameron; Joe Sasadeusz; Paul Desmond; Stephen Locarnini; Gregory J Dore; Kiat Ruxrungtham; Sharon R Lewin
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

Review 6.  Immune checkpoint blockade in infectious diseases.

Authors:  Michelle N Wykes; Sharon R Lewin
Journal:  Nat Rev Immunol       Date:  2017-10-09       Impact factor: 53.106

7.  IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection.

Authors:  Abhishek Das; Gidon Ellis; Celeste Pallant; A Ross Lopes; Pooja Khanna; Dimitra Peppa; Antony Chen; Paul Blair; Geoffrey Dusheiko; Upkar Gill; Patrick T Kennedy; Maurizia Brunetto; Pietro Lampertico; Claudia Mauri; Mala K Maini
Journal:  J Immunol       Date:  2012-09-12       Impact factor: 5.422

Review 8.  Therapeutic vaccination for treatment of chronic hepatitis B.

Authors:  Tamsin Cargill; Eleanor Barnes
Journal:  Clin Exp Immunol       Date:  2021-06-08       Impact factor: 5.732

9.  Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy.

Authors:  Minfeng Liang; Shiwu Ma; Xiaoxiong Hu; Bin Zhou; Junchang Zhang; Jinjun Chen; Zhanhui Wang; Jian Sun; Xiaolin Zhu; William Abbott; Jinlin Hou
Journal:  Virol J       Date:  2011-02-14       Impact factor: 4.099

10.  Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients.

Authors:  Juanjuan Zhao; Yonggang Li; Lei Jin; Shuye Zhang; Rong Fan; Yanling Sun; Chunbao Zhou; Qinghua Shang; Wengang Li; Zheng Zhang; Fu-Sheng Wang
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.